Cancer Prevention Vaccines
About Cancer Prevention Vaccines
Some cancers are caused by infections, and vaccines can prevent them. The HPV vaccine protects against cervical and several other cancers, and the hepatitis B vaccine helps prevent liver cancer. Researchers are also developing vaccines to stop cancer from developing or returning.
The Cancer Prevention Vaccines session at Cancer Research 2027 covers prevention and therapeutic vaccines. It links closely with causes of cancer, which explores the infections behind many cancers.
Vaccines against HPV and hepatitis B are among the most effective cancer prevention tools available. They work best when given before a person is exposed to the virus. High vaccination rates protect whole communities. Many countries are now aiming to eliminate cervical cancer through vaccination and screening.
Key Topics in Cancer Prevention Vaccines
• HPV vaccination and cervical cancer elimination
• Hepatitis B vaccination and liver cancer
• Vaccine uptake and hesitancy
• Vaccination programmes in Asia-Pacific
• Therapeutic cancer vaccines
• Personalised neoantigen vaccines
• Vaccines for people at high inherited risk
• Vaccine safety and monitoring
• Cost-effectiveness of cancer vaccines
• Combining vaccines with screening
Recent Advances in Cancer Prevention Vaccines
HPV vaccination is leading to large falls in cervical pre-cancer and cancer, and many countries are working towards cervical cancer elimination. Combining vaccination with screening from cancer detection and diagnosis is speeding this progress.
Personalised mRNA vaccines are being tested to prevent cancer returning after treatment, part of advances in cancer research and treatment. Vaccine programme impact is tracked through cancer epidemiology.
Single-dose HPV vaccination is making programmes simpler and cheaper. Countries with high coverage are already seeing large falls in cervical pre-cancer. Research is continuing on vaccines that could treat existing cancers or prevent them returning. Efforts are also focused on reaching groups with low vaccine uptake.
Who Should Attend the Cancer Prevention Vaccines Session
• Public health professionals and vaccine researchers
• Gynaecologists and hepatologists
• Oncologists and immunologists
• Primary care and immunisation staff
• PhD students and early-career researchers
• Vaccine industry and policy professionals
Why Present Your Research in Cancer Prevention Vaccines
Cancer Research 2027 brings prevention researchers together with clinicians and policy makers. You can share results and connect with colleagues in cancer and its relevance with other diseases studying links between infection and cancer. Prevention research has a wide impact on public health. Sharing your findings here can support vaccination programmes in other countries.
Frequently Asked Questions
Can I present research on vaccine uptake?
Yes. Uptake, hesitancy and programme studies are welcome.
Does this session include therapeutic vaccines?
Yes. Therapeutic and personalised cancer vaccines fit this session.
When and where is Cancer Research 2027?
Cancer Research 2027 takes place from 8 to 10 March 2027 at Village Hotel Changi, Singapore, and online.